B. Chang

A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).

M. Michaelson, H. Sandler, G. Swanson, 2017, International journal of radiation oncology, biology, physics.

A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (Trial ****)

M. Michaelson, H. Sandler, G. Swanson, 2017 .

Stereotactic Body Radiation Therapy: A Comprehensive Review

R. Timmerman, B. Chang, 2007, American journal of clinical oncology.

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.

M. Michaelson, A. Zietman, H. Sandler, 2023, European urology oncology.

Improving the Clinical and Cost Efficiency of Peripheral Blood Smear Review

Lei Chen, N. Golardi, B. Chang, 2014 .

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.

K. Rahbar, M. Morris, M. Desilvio, 2023, The Lancet. Oncology.